Clinical Trial Search Results
NCI-COG PEdiatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations
This is a Phase 2 study of a drug called LOXO-292. In a Phase 2 study, the goal is to find out what effects, good and/or bad, a drug has on your tumor or type of cancer. LOXO-292 is experimental because it has not been proven t ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors
This is a Phase 2 study of a drug called LY3023414. In a Phase 2 study, the goal is to find out what effects, good and/or bad, a drug has on your tumor or type of cancer.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
The main goal is to test any good and bad effects of the study drug olaparib on your tumor. A second goal of the study is to evaluate side effects that might be caused by olaparib and to learn more about the pharmacology (how y ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
The main goal of this study is to test any good and bad effects of the palbociclib on your tumor. A second goal of the study is to evaluate side effects that might be caused by palbociclib.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate)in Patients with Tumors Harboring Activating MAPK Pathway Mutations
The main goal is to test any good and bad effects of the study drug selumetinib (AZD6244 hydrogen sulfate) on your tumor. A second goal of the study is to evaluate side effects that might be caused by selumetinib (AZD6244 hydro ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations
This is a Phase 2 study of a study drug called tipifarnib. The main goal of the study is to find out what effect, good and/or bad effects the study drug tipifarnib may have on your tumor. A second goal of the study is to evalua ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring BRAF V600 Mutations
You are being asked to participate in this study because you have relapsed or refractory tumor without a proven treatment strategy for cure. The main goal is to test any good and bad effects of the study drug vemurafenib on you ...
NN9388-7700: Efficacy and safety of co-administered cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (cagrisema s.c. 2.4 mg/2.4 mg) once-weekly compared to semaglutide, cagrilinitide and placebo in people with chronic kidney disease and type 2 diabetes.
Study Purpose: The purpose of this study is to see whether CagriSema can lower kidney damage. This will be compared to the effects of semaglutide, cagrilintide and placebo. Study Duration: Approximately 35 weeks Study Commitmen ...
North American Pediatric Renal Trials Collaborative Studies (NAPRTCS)
NAPRTCS is a research effort that was organized in 1987 by a group of physicians and surgeons committed to the success of pediatric renal transplant.